Biologic and Small Molecule Treatment for Seborrheic Dermatitis: An Evidence-Based Review
- PMID: 39397369
- DOI: 10.1177/12034754241290826
Biologic and Small Molecule Treatment for Seborrheic Dermatitis: An Evidence-Based Review
Keywords: Janus kinase inhibitor; biologic; phosphodiesterase-4; seborrheic dermatitis; small molecule; systematic review.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Asfandyar Mufti has been a speaker for AbbVie and Janssen. Dr Jensen Yeung has been an advisor, consultant, speaker, and/or investigator for AbbVie, Allergan, Amgen, Astellas, Bausche, Baxalta, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Fresenius Kabi, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Xenon. The remaining authors Mr Sood, Mr Perlmutter, Dr Maliyar, and Dr Abduelmula have no relevant disclosures.
Publication types
LinkOut - more resources
Full Text Sources